sb 203580 has been researched along with 3-hydroxyflavone in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (3-hydroxyflavone) | Trials (3-hydroxyflavone) | Recent Studies (post-2010) (3-hydroxyflavone) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 3,657 | 84 | 2,242 |
| Protein | Taxonomy | sb 203580 (IC50) | 3-hydroxyflavone (IC50) |
|---|---|---|---|
| Pyruvate kinase PKM | Homo sapiens (human) | 1.75 | |
| Cytochrome P450 1B1 | Homo sapiens (human) | 0.09 | |
| Aurora kinase B | Homo sapiens (human) | 4.29 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, DY; Huh, JE; Jeon, G; Lee, JD; Park, DS; Woo, HS; Yang, HR | 1 |
1 other study(ies) available for sb 203580 and 3-hydroxyflavone
| Article | Year |
|---|---|
Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cell Movement; Cell Proliferation; Collagen Type II; Cytokines; Disease Models, Animal; Enzyme Inhibitors; Fibroblasts; Flavonoids; Flavonols; Humans; Hypersensitivity, Delayed; Imidazoles; Interleukin-1beta; Mice; Mice, Inbred DBA; Neovascularization, Pathologic; Oxazolone; Protein Kinases; Pyridines; Rats; Rats, Sprague-Dawley; Rhus; Synovial Membrane; Vascular Endothelial Growth Factor A | 2009 |